AMS Biotechnology (Amsbio) has introduced a new range of over 30 independently developed and manufactured organoid culture-related cytokines for researchers working with stem cells and induced pluripotent stem cells (iPSCs).  

The new cytokine range has been tailored and validated in organoid culture, ensuring high compatibility and enabling more controlled and reproducible research outcomes.

Organoids have rapidly become a key cell culture tool in biomedical research, widely applied in development and disease modeling, precision medicine, toxicology studies and regenerative medicine.

AMSBIO’s latest portfolio offers a suite of cytokines for organoid culture, including Activin A, BMP-4, EGF, FGF-4, FGF-10, FGFb, FGF8b, HGF, IGF1, Noggin, R-Spondin 1, Shh, and Wnt3a. These cytokines feature endotoxin levels below 0.01 EU/μg and are characterised by high activity, high purity, and high lot-to-lot consistency.

Supplied as ready-to-use formulations, these products are extremely easy to use with simple and convenient protocols. Beneficially, each cytokine for organoid culture kit is highly effective at preserving the structural and genetic characteristics of normal mammalian tissues, maintaining the heterogeneity of the original tissue. Using these products, high-quality organoids can routinely be successfully cultivated within just 4-7 days.

All cytokines supplied by Amsbio have been validated in in vitro models, including human tumour organoids such as pituitary adenoma organoids and breast cancer organoids; human normal organoids such as iPSC-derived intestinal organoids as well as mouse normal organoids such as intestinal and pancreas organoids.